

LIBELED: On or about 7-11-61, S. Dist. Ind.

CHARGE: 502(a)—while held for sale, the labeling of the article contained false and misleading representations that the article was adequate and effective as a treatment for relief of flu, colds, chills, rheumatism, grippe, and associated conditions; and 502(f) (2)—the labeling of the article failed to bear the warning statement "Keep out of reach of children."

DISPOSITION: 10-20-61. Default—destruction.

6870. Cobasal tablets and Cobaden injection. (F.D.C. No. 46588. S. Nos. 97-902 R, 97-904 R.

QUANTITY: 21 cases, 12 100-tablet btls. each, and 10 1,000-tablet btls. of *Cobasal*; and 48 vials of *Cobaden injection*, at Rensselaer, N.Y., in possession of Rand Pharmaceutical Co., Inc.

SHIPPED: (*Cobasal tablets*) 2-1-61, from Worcester, Mass.; (*Cobaden injection*) 4-24-61, from Decatur, Ill.

LABEL IN PART: (Btl.) "Cobasal * * * Each 2 Tablets contains: Dipyrone 0.125 Gm Para-amino-benzoic Acid 8 gr. Salicylamide 6 gr. Vitamin B-12 Activity 5 mcg. Distributed by Rand Pharmaceutical Company, Inc., Rensselaer, N.Y. Caution: * * * Dosage: 2 tablets." and (vial and ctn.) "10 cc. No. 125 Multiple Dose Sterile Vial Cobaden * * * Caution * * * Manufactured for Rand Pharmaceutical Co., Inc., Rensselaer, N.Y. Each 1 cc. contains: Adenosine-5-Monophosphoric Acid 25 mg. (present as Sodium Salt) Vitamin B-12 (Crystalline) 60 mcg. * * * Intramuscular."

ACCOMPANYING LABELING: Leaflets entitled "Cobaden Adenosine-5-monophosphoric acid plus Vitamin B₁₂," "Adenosine with Vitamin B₁₂" and "Cobasal (Rand) A new Anti-Rheumatic * * * Alone or in conjunction with * * * Cobaden."

LIBELED: 10-27-61, N. Dist. N.Y.

CHARGE: 502(a)—while held for sale, (*Cobasal tablets*) the labeling contained false and misleading representations that the article was adequate and effective for the treatment of neuritis; pruritus; pruritus due to penicillin sensitivity; chronic venous insufficiency; renal and gall-bladder colics; pneumonia; meningeal inflammations; cholelithiasis; iritis; and herpes; and to promote growth and body development; and the labeling also contained false and misleading representations that there were no contraindications for use of the article; and (*Cobaden injection*) the labeling contained false and misleading representations that the article was adequate and effective for the treatment of bursitis; osteoarthritis; pruritus ani, vulvae, and scroti; pruritus associated with penicillin reaction; and chronic venous insufficiency; and 502(f) (1)—(*Cobasal tablets*) the labeling failed to bear adequate directions for use, since its labeling failed to bear adequate information for use of the drug, including relevant hazards, contraindications, side effects, and precautions under which practitioners licensed by law to administer the drug, could use it safely and for the purposes for which it was intended.

DISPOSITION: 1-4-62. Default—destruction.

6871. Devine's remedies. (F.D.C. No. 46474. S. Nos. 6-282/5 T.)

QUANTITY: 144 10-oz. pkgs. of *10/2 Corn and Callous Reducer*; 864 5- or 3- or 1-fluid oz. tubes of *Kool-Foot Powder*; 576 3¾-oz boxes of *Per-Fo Footbath*; and 720 envelopes of *Karbo-Silekon Corn Reducer*, at Boston, Mass., in possession of Darryl Jensen.